Overview
Novalis Biotech invests in innovative healthcare concepts from incorporation through Series A, with a focus on enabling technologies including research and manufacturing tools, bioinformatics, genomics, diagnostics, and digital health. The firm provides funding, professional and academic connections, and business strategy support to early-stage startups.
In the news
- It's not often that the good people of SynBioBeta mention work that one of our portfolio companies has done! A very big congratulations to the myNEO Therapeutics team!!
- Very good to see none other than Eric Topol confirming the business case for our portfolio company H42.ai (That said, many of his posts have a direct link to one or other of our portfolio companies.) H42 helps its customers analyse the meaning of epigenetic changes in relation to age related diseases in the broadest possible sense. They also get involved in the actual testing, as well as the development of biomarkers.
- When GSK commits $110M for biological data — not AI models — the message is clear. The headline: GSK-backed Relation Therapeutics launches a $110M deal and unveils MORGAN, a cell biology foundation model. The real story: GSK is paying for the PETASCALE cellular perturbation DATA that makes the model work. Not model licensing. Data manufacturing. At scale. Why does this matter? Because the bottleneck in AI drug discovery has shifted. We have enough models. What we don't have is training data that is: ✅ Homogeneous (not a
- myNEO in the news!
- The microcarrier market is booming — valued at $2.4-3.8B in 2026, projected to $5.5-14.9B by 2035 (11-16% CAGR). Cell and gene therapy manufacturing is the main driver, plus vaccine production and cell culture. Carroucell's sol-gel microcarrier technology is a genuinely differentiated play in this growing space — bioactive glass microstructures that can be functionalised for specific cell types, with validation from EFS (French Blood Establishment) and many others. They're competing with Cytiva, Sartorius, and Corning but with a
- Digital biomarkers + protein biomarkers = the future of neurodegenerative disease diagnosis. Modality.AI is at the forefront of building the digital side of that equation — speech, voice, and cognitive markers that can be deployed at scale. Exactly the kind of multimodal approach the field needs. Proud to be backing this team. 🧠
- Clinical trials need modernizing. CLOUDS OF CARE is proving it can be done — and at global scale. First fully global at-home video EEG in a pivotal Phase 3 trial (US, Europe, Asia, Australia). For kids with rare GRIN disorders, that means overnight EEGs at home, not in hospital. Same data quality. Radically better experience. Proud to support this team. 👏
- Happy 250th Independence Day to our American friends, partners, and the teams behind our US-based portfolio companies and subsidiaries. Novalis Biotech is proud to bridge the Atlantic, fostering innovation in life sciences through a truly global network. We celebrate this milestone with you. #IndependenceDay #LifeSciences #Innovation #NovalisBiotech"
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.